Publications

Spotlight Publication

Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)

American Society for Clinical Oncology (ASCO) GI

Jan 18
- Jan 20, 2024
Neoadjuvant botensilimab plus balstilimab (BOT/BAL) in resectable mismatch repair proficient and deficient colorectal cancer: NEST-1 clinical trial.
Kasi, et. al.

Filter by

Balstilimab (PD-1 Antagonist)

Gynecologic Oncology

Aug 25, 2021
Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer.
O’Malley, et al.
Balstilimab (PD-1 Antagonist)

European Society for Medical Oncology (ESMO) Virtual

Sep 16
- Sep 21, 2021
Balstilimab Alone or in Combination with Zalifrelimab as Second-line Treatment for Patients with Previously Treated Recurrent/metastatic Cervical Cancer: a Randomized, Placebo-Controlled Phase II Trial (RaPiDS/GOG-3028).
Randall, et al.
Balstilimab (PD-1 Antagonist)

European Society for Medical Oncology (ESMO) Virtual

Sep 16
- Sep 21, 2021
Balstilimab (anti-PD-1) in Combination with Zalifrelimab (anti-CTLA-4): Final Results from a Phase 2 Study in Patients (pts) with Recurrent/metastatic (R/M) Cervical Cancer (CC).
O’Malley, et al.
AGEN2373 (CD137 Agonist)

Society for Immunotherapy of Cancer (SITC)

Nov 7
- Nov 11, 2018
AGEN2373 is a Conditionally-Active Agonist Antibody Targeting the Co-Stimulatory Receptor CD137 for the Treatment of Human Malignancies.
Galand, et al.
AGEN2373 (CD137 Agonist)

Society for Immunotherapy of Cancer (SITC)

Nov 9
- Nov 14, 2020
AGEN2373 is a CD137 agonist antibody designed to leverage optimal CD137 and FcγR co-targeting to promote antitumor immunologic effects.
Galand, et al.
AGEN2373 (CD137 Agonist)

American Society of Clinical Oncology (ASCO)

Jun 3
- Jun 7, 2021
Initial Findings of the First-in-human Phase I Study of AGEN2373, a Conditionally Active CD137 Agonist Antibody, in Patients (pts) With Advanced Solid Tumors.
Tolcher, et al.
AGEN1571 (ILT2 Antagonist)

American Association for Cancer Research (AACR)

Apr 8
- Apr 12, 2022
AGEN1571 is a novel high-affinity ILT2 antagonist antibody that promotes adaptive and innate immune responses.
Udartseva, et al.
AGEN1327 (TIGIT Antagonist)

Cancer Cell

Jun 11, 2018
Selective FcgR Co-Engagement on APCs Modulates the Activity of Therapeutic Antibodies Targeting T Cell Antigens.
Waight, et al.
AGEN1327 (TIGIT Antagonist)

Society for Immunotherapy of Cancer (SITC)

Nov 9
- Nov 14, 2020
Anti-TIGIT antibodies require enhanced FcγR co-engagement for optimal T and NK cell-dependent anti-tumor immunity.
Ward, et al.
AGEN1327 (TIGIT Antagonist)

American Association for Cancer Research (AACR)

Mar 29
- Apr 3, 2019
FcgR Co-Engagement by Anti-TIGIT Monoclonal Antibodies Enhances T cell Functionality and Antitumor Immune Responses.
Chand, et al.